Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics develops medicines for immune-mediated diseases. Lead product candidate reproxalap treats dry eye diseases in Phase III trials. Other products include ADX-629 for COVID-19, atopic asthma, psoriasis, and alcohol intoxication; ADX-2191 for retinitis pigmentosa and rare retinal diseases; ADX-246 for systemic immune-mediated disease; and ADX-248 for geographic atrophy. The company was previously Aldexa Therapeutics, Inc. before changing its name in 2014. It was incorporated in 2004 and is based in Lexington, Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

5.4 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.7